The United States' withdrawal from the World Health Organization, effective January 22, 2026, removes its largest single funder, leaves substantial dues unpaid and forces a redesign of global health financing, coordination and treaty-making over coming decades.
Verdict: Trump's executive order 14155 and State Department notification set a clear legal path for US withdrawal, with effect on January 22, 2026 (White House, 2025-01-20; UN, 2025-01-21). WHO and UN officials warn that the loss of roughly 18% of WHO funding and large unpaid US arrears threaten tuberculosis, polio and emergency programs (WHO, 2025-01-21; TBS, 2025-01-22). Given polarized US politics, a medium-term absence from WHO is likely, but not irreversible (STAT, 2026-01-21).
A future US administration re-enters WHO within 5-8 years under a renegotiated financial and governance framework, perhaps with clearer accountability and burden-sharing. Interim gaps are partially filled by other donors and innovative financing, limiting damage to core disease programs. The episode catalyzes constructive reforms in WHO and more diversified funding streams, leaving the system somewhat stronger by the mid-2030s.
The US remains outside WHO for at least a decade but maintains selective cooperation through project-specific agreements, bilateral deals and informal scientist-to-scientist links. WHO adapts by trimming some activities, prioritizing high-burden countries and courting other donors, including emerging economies and philanthropies. Governance becomes more multipolar, with the US influential but no longer structuring the health agenda from inside the agency.
Funding shortfalls and political strain significantly weaken WHO's emergency and normative capacities just as new outbreaks emerge. Fragmented blocs create overlapping health initiatives, leading to duplicated efforts, inconsistent guidance and slower responses, especially in fragile states. One or more major pandemics or cross-border outbreaks have worse outcomes than they would have under a better-funded, more cohesive WHO system.
Either a catastrophic pandemic or a major geopolitical realignment forces a wholesale redesign of global health governance. This could produce a new treaty-based agency or a networked system where WHO is only one node among several powerful regional centers, with or without US membership. Conversely, sustained domestic backlash to isolationism might push a dramatic US re-engagement on unusually generous terms.
Developments: Within a year of the withdrawal taking effect, WHO's budget shows a clear hole where US assessed and many voluntary contributions once were. Program managers begin scaling back or restructuring activities in areas like polio, TB, emergency response and technical assistance, prioritizing highest-burden settings. US agencies shift to more bilateral partnerships and strengthen domestic biosecurity and surveillance structures outside the WHO framework.
Risks: If bridging finance is slow, some country offices may reduce staffing, weakening outbreak detection and routine support. Political signaling from Washington could discourage other skeptical states from fully funding WHO, amplifying the shortfall. Confusion over legal obligations in ongoing projects might delay vaccine and commodity deliveries in vulnerable countries.
Outlook: In the first year, operational disruption is significant but not yet catastrophic. Many actors assume the situation could still be reversed by US politics, delaying deeper structural changes. The balance between temporary turbulence and entrenched disengagement begins to tilt toward the latter if no re-entry signals emerge.
Developments: By year two, WHO has completed a cycle of internal reprioritization, consolidating some regional operations and focusing on core mandates like surveillance, norms and select disease programs. Alternative donors, including EU states, China, Gulf countries and philanthropies, plug parts of the gap, sometimes attaching new conditions. US global health agencies refine their own strategies, emphasizing bilateral influence and domestic readiness over multilateral leadership.
Risks: New donors may steer programs toward their strategic interests, which may not perfectly align with global burden or equity needs. Governance tensions increase as some member states question whether voting shares and board representation should better match who is now paying. The risk grows that competing regional initiatives could pull talent and focus away from WHO, further weakening its coordinating role.
Outlook: After two years, a new equilibrium forms with a leaner, more politically contested WHO. The agency survives but with reduced flexibility and prestige, especially in Washington. The window for an easy US return narrows as other stakeholders adapt to a post-US status quo.
Developments: Three years out, negotiations on the Pandemic Agreement and IHR amendments proceed without US participation or with only observer-style engagement. Other blocs may adopt stricter or more expansive health emergency rules while US domestic law evolves on a separate track. WHO guidance on issues like data sharing, travel advisories and research oversight increasingly reflects non-US priorities and legal systems.
Risks: Divergent standards complicate cooperation during emergencies, especially if companies or researchers must navigate conflicting rules. States caught between US and WHO-aligned regimes may hesitate to share data or samples promptly, fearing legal or political repercussions. Normative fragmentation weakens the universal authority of WHO recommendations, eroding compliance even among remaining members.
Outlook: By year three, the governance gap between US and WHO frameworks is visible and operationally relevant. This makes ad hoc collaboration harder just when crises demand speed and trust. Re-aligning standards later would be politically and technically costly.
Developments: Five years after exit, WHO's funding mix and leadership coalitions look durably different, with a more prominent role for non-Western donors and coalitions. The US continues to run substantial global health programs, but through USAID, CDC, DFC and partnerships that only sometimes align with WHO. Some regional bodies and philanthropic alliances emerge as specialized centers for certain diseases or technologies, operating alongside but not under WHO.
Risks: If coordination across these actors remains weak, duplicative pilots and misaligned investment could leave key gaps, such as underfunded primary care or neglected diseases. Emergency response might depend more on which bloc is affected, risking unequal protection and geopolitical bargaining over aid. A major crisis could expose these seams, causing avoidable delays and higher mortality.
Outlook: At five years, the world likely operates in a more fragmented health governance environment. While innovation and diversification have benefits, they come with higher coordination costs and political friction. A US return to WHO would now require more complex negotiations and compromises on both sides.
Developments: After a decade, institutional routines, staffing patterns and partnerships are deeply adapted to a US-outside-WHO reality. Younger professionals and policymakers may view US dominance in WHO as a historical anomaly rather than a baseline. New treaties or frameworks on antimicrobial resistance, One Health or digital health may be negotiated with minimal formal US input, though US experts still influence through scientific networks.
Risks: Entrenched fragmentation increases the risk that global public goods-like surveillance data, open pathogen repositories and equitable countermeasure access-remain underprovided. If geopolitical rivalry intensifies, health cooperation may become more transactional and tied to broader security bargains. Slow, uneven progress against TB, HIV and emerging infections could deepen mistrust in multilateral tools among affected populations.
Outlook: Ten years on, reversing course would involve rebuilding not just funding streams but trust, representation and institutional culture. The most likely outcome is a permanently more plural, more politicized global health landscape. Whether this delivers better or worse outcomes depends on how well new mechanisms substitute for lost cohesion.
Developments: Two decades out, successor systems to today's WHO-centric order may be clearer, with strong regional health communities in Africa, Asia and the Americas. WHO could function more as a convening and standard-setting umbrella while day-to-day implementation rests with powerful regional entities. The US might anchor one or more of these regional systems, even if it never fully rejoins WHO.
Risks: Persistent inequities between regions with strong institutions and those without could widen global health outcome gaps. Competition for influence among regional blocs can spill into health, affecting where factories, stockpiles and research centers are located. Environmental change, migration and urbanization may interact with uneven governance to produce highly variable resilience to shocks.
Outlook: At 20 years, global health governance is likely a patchwork of overlapping institutions, with WHO one important node among many. The original US exit will be seen as a key turning point in this evolution. The quality of outcomes will depend on whether new structures manage to coordinate despite political rivalries.
Developments: Half a century from now, today's crisis will be a distant precedent shaping institutional design choices. Either a more integrated, legally robust global health authority emerges after repeated shocks or a stable, decentralized network of regional and thematic bodies dominates. The specific role of WHO and the memory of US withdrawal will influence legal doctrines on funding obligations, exit rights and emergency powers.
Risks: If repeated failures during pandemics are traced to fragmented authority and underfunding, public trust in international cooperation could be severely damaged. Conversely, concentration of power in a single global authority without accountability could trigger new political backlashes and exits. Technological change, including AI-driven surveillance and biotech, might outpace governance, creating new ethical and security dilemmas.
Outlook: In 50 years, the system may look very different, but debates over sovereignty, fairness and effectiveness will echo those around the 2026 US exit. Whether that exit is remembered as a cautionary tale or a necessary shock for reform will depend on intervening crises and adaptations. Health outcomes, not institutional pride, will be the ultimate measure.